Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $4.7M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer | Jun 22 '26 | Option Exercise | $1.76 | 580,187 | $1,021,116 | 983,947 | Jun 22 08:18 PM |
| Lowrance David L | Chief Financial Officer | Jun 22 '26 | Sale | $5.68 | 394,528 | $2,241,432 | 536,032 | Jun 22 08:18 PM |
| Lowrance David L | Officer | Jun 22 '26 | Proposed Sale | $5.65 | 394,528 | $2,229,000 | — | Jun 22 03:09 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.